康泰生物：三价流感病毒裂解疫苗（MDCK细胞）药物临床试验获批准

Core Viewpoint - Kangtai Biological (300601) has received approval from the National Medical Products Administration for clinical trials of its trivalent influenza virus split vaccine, indicating a significant advancement in its product pipeline [1] Company Summary - The trivalent influenza virus split vaccine is developed in collaboration with Lanzhou Bailing Biotechnology Co., Ltd. [1] - The vaccine is intended for individuals aged 3 years and older, aiming to stimulate the immune system to produce antibodies against influenza viruses [1] Industry Summary - The approval for clinical trials reflects ongoing efforts in the biopharmaceutical industry to enhance vaccine development, particularly in response to seasonal influenza outbreaks [1]